SSGJ-707 / 3SBio, Pfizer - LARVOL DELTA

A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC. (ASCO 2025) - P2 | "The increase of SSGJ-707 affinity for PD-1 was 10-fold more than that of Ivonescimab in the presence of VEGF. SSGJ-707 monotherapy demonstrated promising efficacy results in treatment naive advanced NSCLC with manageable safety profile. Monotherapy and combination trials with chemotherapy for NSCLC are still ongoing. Research Sponsor: 3S BIO.COM."

Clinical • IO biomarker • Metastases • Monotherapy • P2 data • Dyslipidemia • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • PD-1

Pfizer Enters into Exclusive Licensing Agreement with 3SBio (Pfizer Press Release) - "Pfizer...announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio...for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors....3SBio plans to initiate the first Phase 3 study in China in 2025. Under the terms of the agreement, 3SBio and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd. will grant Pfizer an exclusive global license to develop, manufacture and commercialize SSGJ-707 worldwide, excluding China....3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion..."

Licensing / partnership • New P3 trial • Colorectal Cancer • Gynecologic Cancers • Non Small Cell Lung Cancer

SSGJ-707 in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=420 | Not yet recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

IO biomarker • New P3 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

707 Injection (Anti-VEGF/PD-1 Bispecific Antibody) Granted Breakthrough Therapy Designation by NMPA (HKEXnews) - "On 17 April, 2025, the anti-VEGF/PD-1 bispecific antibody (R&D code: 707 Injection), independently developed by 3SBio, was granted a Breakthrough Therapy Designation ('BTD') by China’s National Medical Products Administration ('NMPA'). The designated indication is the first-line treatment of PD-L1 positive locally advanced or metastatic non-small cell lung cancer ('NSCLC'). 707 Injection is a bispecific antibody targeting VEGF/PD-1, independently developed by 3SBio based on its proprietary CLF2 platform."

Breakthrough therapy • Non Small Cell Lung Cancer

A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Endometrial Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - P2 | N=130 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients (clinicaltrials.gov) - P2 | N=235 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Phase 2 Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients (clinicaltrials.gov) - P2 | N=80 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Metastases • New P2 trial • Endometrial Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Metastases • New P2 trial • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients (clinicaltrials.gov) - P2 | N=235 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Combination therapy • Metastases • New P2 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Metastases • Monotherapy • New P2 trial • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor